Institutional investors hold a majority ownership of DVAX through the 84.00% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2013, these large investors purchased a net $3.1 million shares.
| Individual stakeholders | 8.77% |
| Mutual fund holders | 50.11% |
| Other institutional | 33.89% |